Literature DB >> 2487532

Peripheral hemodynamic effects of ibopamine in patients with congestive heart failure. A placebo-controlled, double-blind study.

C Longhini1, L Ansani, G F Musacci, S Aggio, E Baracca, T Toselli, P Ghirardi.   

Abstract

Under double-blind conditions, 150 mg of ibopamine (di-isobutyric ester of N-methyldopamine) or placebo were given orally to 11 patients with congestive heart failure; after 3 hours, 50 mg of sulpiride were administered intramuscularly. Peripheral hemodynamics were evaluated at the level of the forearm using strain-gauge plethysmography. Ibopamine increased arterial blood flow and venous capacity and decreased arterial peripheral resistance; these effects were counteracted by sulpiride. No significant changes were observed after placebo and sulpiride. These findings confirm the vasodilating effects of ibopamine on peripheral hemodynamics and its utility in patients for the treatment of congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2487532     DOI: 10.1007/bf01883865

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  16 in total

1.  THE INVESTIGATION OF PERIPHERAL ARTERIAL DISEASE BY STRAIN GAUGE PLETHYSMOGRAPHY.

Authors:  K MYERS
Journal:  Angiology       Date:  1964-07       Impact factor: 3.619

2.  Peripheral pre- and post-synaptic dopamine receptors: are they different from dopamine receptors in the central nervous system?

Authors:  L I Goldberg; J D Kohli
Journal:  Commun Psychopharmacol       Date:  1979

3.  Effect of ibopamine on peripheral haemodynamics.

Authors:  C Longhini; G F Musacci; L Ansani; T Toselli; M Artioli; L Bianco; P Ghirardi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Acute effects of ibopamine hydrochloride on hemodynamics, plasma catecholamine levels, renin activity, aldosterone, metabolism and blood gas in patients with severe congestive heart failure.

Authors:  T Nakano; Y Morimoto; Y Kakuta; T Konishi; T Kodera; M Kanamaru; H Takezawa
Journal:  Arzneimittelforschung       Date:  1986-12

5.  Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.

Authors:  S I Rajfer; J D Rossen; F L Douglas; L I Goldberg; T Karrison
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

6.  Ibopamine in very severe congestive heart failure: pilot haemodynamic invasive assessment.

Authors:  J Col; E Mievis; M Reynaert
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Hemodynamic evaluation of ibopamine in patients with refractory congestive heart failure.

Authors:  F Humar; T Morgera; P Maras; F Camerini
Journal:  Arzneimittelforschung       Date:  1986-02

8.  Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure.

Authors:  L Sannia; G V Ibba; M Castellaccio; L Dore
Journal:  Arzneimittelforschung       Date:  1986-02

9.  Evaluation of acute hemodynamic effects and pharmacokinetic behaviour of ibopamine in patients with severe heart failure.

Authors:  C De Vita; E Triulzi; S Devizzi; G Colombo; M Palvarini; F Pocchiari; R Pataccini
Journal:  Arzneimittelforschung       Date:  1986-02

10.  The dopamine congener, ibopamine, in congestive heart failure.

Authors:  J H Ren; D V Unverferth; C V Leier
Journal:  J Cardiovasc Pharmacol       Date:  1984 Sep-Oct       Impact factor: 3.105

View more
  2 in total

1.  Acute effect of ibopamine and isosorbide mononitrate on blood volume distribution in congestive heart failure.

Authors:  N D Holman; O S Hoekstra; A B Groeneveld; A J Schneider; W G de Voogt; J van der Meer
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 2.  Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.

Authors:  C Spencer; D Faulds; A Fitton
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.